FR21C1004I2 - Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe - Google Patents

Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe

Info

Publication number
FR21C1004I2
FR21C1004I2 FR21C1004C FR21C1004C FR21C1004I2 FR 21C1004 I2 FR21C1004 I2 FR 21C1004I2 FR 21C1004 C FR21C1004 C FR 21C1004C FR 21C1004 C FR21C1004 C FR 21C1004C FR 21C1004 I2 FR21C1004 I2 FR 21C1004I2
Authority
FR
France
Prior art keywords
treatment
ides
pyogenes
proteinase
autoimmune diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1004C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511769A external-priority patent/GB0511769D0/en
Priority claimed from GB0605781A external-priority patent/GB0605781D0/en
Application filed by Hansa Biopharma AB filed Critical Hansa Biopharma AB
Publication of FR21C1004I1 publication Critical patent/FR21C1004I1/fr
Application granted granted Critical
Publication of FR21C1004I2 publication Critical patent/FR21C1004I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR21C1004C 2005-06-09 2021-02-04 Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe Active FR21C1004I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0511769A GB0511769D0 (en) 2005-06-09 2005-06-09 Treatment
GB0605781A GB0605781D0 (en) 2006-03-22 2006-03-22 Treatment
PCT/EP2006/005454 WO2006131347A2 (en) 2005-06-09 2006-06-08 Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection

Publications (2)

Publication Number Publication Date
FR21C1004I1 FR21C1004I1 (enExample) 2021-03-26
FR21C1004I2 true FR21C1004I2 (fr) 2022-01-14

Family

ID=36952007

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1004C Active FR21C1004I2 (fr) 2005-06-09 2021-02-04 Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe

Country Status (14)

Country Link
US (1) US8133483B2 (enExample)
EP (1) EP1901773B1 (enExample)
JP (1) JP5427409B2 (enExample)
CN (1) CN105770871A (enExample)
AT (1) ATE548049T1 (enExample)
AU (1) AU2006256891B2 (enExample)
BE (1) BE2021C505I2 (enExample)
CA (1) CA2611646C (enExample)
ES (1) ES2380950T3 (enExample)
FR (1) FR21C1004I2 (enExample)
NL (1) NL301089I2 (enExample)
PL (1) PL1901773T3 (enExample)
PT (1) PT1901773E (enExample)
WO (1) WO2006131347A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343895B1 (en) * 2000-12-21 2008-06-18 ID Biomedical Corporation Streptococcus pyogenes antigens and corresponding dna fragments
EP2144681A4 (en) 2007-05-04 2011-10-05 Kurt G I Nilsson MATERIAL FOR THE DEPOSITION OF A BIOMOLECULAR
WO2009080278A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Stability testing of antibodies
WO2010089126A2 (en) 2009-02-09 2010-08-12 Roche Glycart Ag Immunoglobulin glycosylation pattern analysis
AU2010240486B2 (en) * 2009-04-22 2014-09-18 Ofir Menashe Microorganism comprising particles and uses of same
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
AU2017214441B2 (en) 2016-02-04 2021-08-19 Genovis Ab New Streptococcal proteases
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CA3149395A1 (en) * 2019-08-01 2021-02-04 Memorial Sloan-Kettering Cancer Center Cells for improved immunotherapy and uses thereof
IL309560B2 (en) 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
CN120078887A (zh) * 2020-09-21 2025-06-03 上海宝济药业股份有限公司 一种药物组合及其应用
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
WO2023116817A1 (zh) * 2021-12-22 2023-06-29 上海宝济药业有限公司 一种免疫球蛋白降解酶IdeE的突变体的用途
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
AU2023383441A1 (en) 2022-11-18 2025-06-05 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof
CN122438692A (zh) * 2023-08-01 2026-07-21 英斯梅德股份有限公司 新型IgG蛋白酶及其使用方法
WO2025047848A1 (ja) 2023-08-30 2025-03-06 アステラス製薬株式会社 ＩｄｅＺ改変体
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
GB202413764D0 (en) 2024-09-18 2024-10-30 Genovis Ab Immunoglobulin proteases and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284747A2 (en) * 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein

Also Published As

Publication number Publication date
NL301089I2 (nl) 2021-02-04
CA2611646A1 (en) 2006-12-14
US20100303781A1 (en) 2010-12-02
PT1901773E (pt) 2012-06-06
WO2006131347A2 (en) 2006-12-14
ATE548049T1 (de) 2012-03-15
BE2021C505I2 (enExample) 2021-05-31
CA2611646C (en) 2015-08-11
AU2006256891A1 (en) 2006-12-14
NL301089I1 (enExample) 2021-01-20
WO2006131347A3 (en) 2007-05-31
PL1901773T3 (pl) 2012-09-28
CN105770871A (zh) 2016-07-20
EP1901773B1 (en) 2012-03-07
JP2008542418A (ja) 2008-11-27
FR21C1004I1 (enExample) 2021-03-26
AU2006256891B2 (en) 2011-08-04
ES2380950T3 (es) 2012-05-21
JP5427409B2 (ja) 2014-02-26
EP1901773A2 (en) 2008-03-26
US8133483B2 (en) 2012-03-13

Similar Documents

Publication Publication Date Title
PT1901773E (pt) Utilização da proteinase ides (de s. pyogenes) para o tratamento de doenças e rejeição de enxertos
FR22C1052I2 (fr) Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes
EP1951273A4 (en) USE OF LACTOBACILLUS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
NO20091736L (no) IL-17-reseptor A-antigenbindende proteiner
WO2008071418A3 (en) Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases
EP1461081A4 (en) ANTI-CD45RB ANTIBODY FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANT ABLUSION
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
MX355256B (es) Anticuerpos anti-il-17a/il-17f de reactividad cruzada y métodos de uso de los mismos.
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
EP2069377A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS
PH12020551805A1 (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
IL209338A0 (en) Pharmaceutical compositions containing anti-cd-3 antibodies
SG170804A1 (en) Pseudomonas aeruginosa outer membrane protein pa0427
EA200702193A1 (ru) Гликозилирование белков
ATE389670T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
FR2889068B1 (fr) Nouvelles fractions proteiques laitieres et leur utilisation pour la prevention ou le traitement des maladies inflammatoires chroniques
FR2858234B1 (fr) Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
ATE442382T1 (de) Ein die mam-domäne enthaltendes protein
EP1846033A4 (en) BLOCKADE OF ELR + CXC CHEMOKINES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
FR2856595B1 (fr) Methodes et compositions pour le traitement de deficits cognitifs.
WO2003014389A3 (en) Method for determining susceptibility to prion disease